Epilepsy Benchmark Stewards. 2014 Epilepsy Benchmarks Area III: Improve Treatment
Options for Controlling Seizures and Epilepsy-Related Conditions Without Side
Effects.  
Dlugos D, Worrell G, Davis K, Stacey W, Szaflarski J, Kanner A, Sunderam S, Rogawski M, Jackson-Ayotunde P, Loddenkemper T, Diehl B, Fureman B, Dingledine R; Epilepsy Curr. 2016 May-Jun;16(3):192-7. PMID: 27330452; PMCID: PMC4913858.

Institute of Neurological Disorders and Stroke (NINDS) Epilepsy Benchmark
Stewards. 2014 Epilepsy Benchmarks Area IV: Limit or Prevent Adverse Consequence 
of Seizures and Their Treatment Across The Lifespan. 
Goldman AM, LaFrance WC Jr, Benke T, Asato M, Drane D, Pack A, Syed T, Doss R, Lhatoo S, Fureman B, Dingledine R; American Epilepsy Society (AES)/National Epilepsy Curr. 2016 May-Jun;16(3):198-205. PubMed PMID: 27330453; PMCID: PMC4913859.

A New Approach for Epilepsy.
Dingledine R, Hassel B. Cerebrum. 2016 May 1;2016.  eCollection 2016 May-Jun. PMID: 27408679; PMCID: PMC4938265.

Inhibition of the prostaglandin E2 receptor EP2 prevents status epilepticus-induced deficits in the novel object recognition task in rats.
Rojas A, Ganesh T, Manji Z, O'neill T, Dingledine R. Neuropharmacology. 2016 Jul 28. pii: S0028-3908(16)30314-8. [Epub ahead of print] PMID: 27477533.

2014 Epilepsy Benchmarks Area II: Prevent Epilepsy and Its Progression.
Galanopoulou AS, Wong M, Binder D, Hartman AL, Powell EM, Roopra A, Staba R, Vezzani A, Fureman B, Dingledine R; American Epilepsy Society (AES)/National Institute of Neurological Disorders and Stroke (NINDS) Epilepsy Benchmarks Stewards. Epilepsy Curr. 2016 May-Jun;16(3):187-91. doi: 10.5698/1535-7511-16.3.187. No abstract available. PMID: 27330451

2014 Epilepsy Benchmarks Area I: Understanding the Causes of the Epilepsies and Epilepsy-Related Neurologic, Psychiatric, and Somatic Conditions. Caplan R, Mefford H, Berl M, Chang B, Lin J, Mazarati A, Fureman B, Dingledine R; American Epilepsy Society (AES)/National Institute of Neurological Disorders and Stroke (NINDS) Epilepsy Benchmark Stewards. Epilepsy Curr. 2016 May-Jun;16(3):182-6. doi: 10.5698/1535-7511-16.3.182. No abstract available. PMID: 27330450

EP2 receptor signaling regulates microglia death. 
Fu, Y, Yang, M, Jiang, J, Ganesh, T, Joe, E, Dingledine, R.(2015). Molecular Pharmacology, 2015 Jul;88(1):161-70.

Inhibition of the prostaglandin EP2 receptor is neuroprotective and accelerates functional recovery in a rat model of organophosphorus induced status epilepticus 
Rojas, A, Ganesh, T, Lelutiu, N, Gueorguieva, P, Dingledine R.(2015). Neuropharmacology, 93, 15-27.

Therapeutic window for cyclooxygenase-2 related anti-inflammatory therapy after status epilepticus. 
Jiang, J, Yang, M, Quan, Y, Gueorguieva, P, Ganesh, T, Dingledine R.(2015). Neurobiology of Disease, 76, 126-136.

Candidate Drug Targets for Prevention or Modification of Epilepsy. 
Varvel, N, Jiang, J, Dingledine R.(2015). Annual Review of Pharmacology and Toxicology, 55, 229-247.

When and How Do Seizures Kill Neurons, and Is Cell Death Relevant to Epileptogenesis?. 
Dingledine R, Varvel, N, Dudeck, F.E.(2014). Issues in Clinical Epileptology: A View from the Bench Advances in Experimental Medicine and Biology , 813, 109-122.

The prostaglandin EP1 receptor potentiates kainate receptor activation via a protein kinase C pathway and exacerbates status epilepticus. 
Rojas, A, Gueorguieva, P, Lelutiu, N, Quan, Y, Shaw, R, Dingledine R.(2014). Neurobiology of Disease, 70, 74-89.

Development of second generation EP2 antagonists with high selectivity. 
Ganesh, T, Jiang, J, Dingledine R.(2014). European Journal of Medicinal Chemistry, 82, 521-535.

Cyclooxygenase-2 in epilepsy. 
Rojas, A, Jiang, J, Ganesh, T, Yang, M, Lelutiu, N, Gueorguieva, P, Dingledine R.(2014). Epilepsia, 55(1), 17-25.

Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection. 
Jiang J and Dingledine R.(2013). Trends Pharmcol Sci, 34(7), 413-23.

EP2 receptor signaling pathways regulate classical activation of microglia. 
Quan Y, Jiang J, Dingledine R.(2013). J Biol Chem., 288(13), 9293-302.

Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation. 
Jiang J, Quan Y, Ganesh T, Pouliot WA, Dudek FE, Dingledine R.(2013). PNAS, 110, 9, 3591-6.

Ionotropic glutamate receptors: regulation by g-protein-coupled receptors. 
Rojas, A. & Dingledine, R. (2013). Molecular Pharmacology, 83, 4, 746-52.

Epigenetics and epilepsy. 
Roopra A, Dingledine R, Hsieh J. (2013). Epilepsia, 53 Suppl 9:2-10.

Role of prostaglandin receptor EP2 in the regulations of cancer cell proliferation, invasion, and inflammation. 
Jiang, J. & Dingledine R. (2013). J Pharmacol Exp Ther., 344, 2, 360-7.

Activation of group I metabotropic glutamate receptors potentiates heteromeric kainate receptors. 
Rojas A, Wetherington J, Shaw R, Serrano G, Swanger S, Dingledine R. (2013). Molecular Pharmacology, 83, 1, 106-121.

Reduction in delayed mortality and subtle improvement in retrograde memory performance in pilocarpine-treated mice with conditional neuronal deletion of cyclooxygenase-2 gene. 
Levin, J., Serrano, G., Dingledine, R. (2012). Epilepsia, 53(8):1411–1420. 

The role of inflammation in epileptogenesis. 
Vezzani, A., Friedman, A., Dingledine, R. (2013). Neuropharmacology,  69:16-24. PMCID: PMC3447120 

Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2. 
Jiang, J., Ganesh, T., Du, Y., Quan, Y., Serrano, G., Qui, M., Speigel, I., Rojas, A., Lelutiu, N., and Dingledine, R. (2012). Proc Natl Acad Sci., 109(8):3149-54. 

Ablation of cyclooxygenase-2 in forebrain neurons is neuroprotective and dampens brain inflammation after status epilepticus. 
Serrano, G.E., Lelutiu, N., Rojas, A., Cochi, S., Shaw, R., Makinson, C.D., Wang, D., FitzGerald, G.A., Dingledine, R. 2011. Journal of Neuroscience, 31 (42), 14850-14860.

Molecular cascades that mediate the influence of inflammation on epilepsy. 
Friedman, A. and Dingledine, R. 2011. Epilepsia, 52 (suppl 3): 33-39.

Blocking eIF4E:eIF4G interaction as a strategy to impair coronavirus replication. 
Cencic, R., Desforges, M., Du. Y., Dingledine, R., Fu, H., Talbot, P., Pelletier, J. 2011. Journal of Virology, 85, 6381-6389.

The Direct Detection of a Single Evoked Action Potential with Magnetic Resonance Spectroscopy in Lumbricus Terrestris. 
Poplawsky AJ, R Dingledine and XP Hu. 2011. NMR in Biomedicine.

A dual readout F2 assay that combines fluorescence resonance energy transfer (FRET) and fluorescence polarization (FP) for monitoring bimolecular interactions. 
Du Y., Nikolovska-Coleska, Z., Qui, M., Li, L., Lewis, I., Dingledine, R., Gee, P., Stuckey, J.A., Krajewski, K., Roller, P.P., Wang, S., Fu, H. 2011. Assay and Drug Development Technologies 9, 4, 382-393..

Unraveling the role of zinc in memory. 
Mott, DD and Dingledine, R. 2011. Proc Nat Acad Sci,108, 8, 3103-3104.

Induction and expression rules of synaptic plasticity in hippocampal interneurons. 
Laezza, F. and Dingledine, R. 2011. Neuropharmacology 60, 720-729.

Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F. 
Cencic, R., Hallb, D.R., Roberta, F., Duc, Y., Minc, J., Lic, L., Quic, M., Lewis, I., Kurtkayac, S., Dingledine, R., Fu, H., Kozakovb, D., Vajdab, S., and Pelletier, 2011. J. Proc Natl Acad Sci. Jan 18, 108 (3), 1046–1051.

Distinct 3'UTRs differentially regulate activitydependent translation of brain-derived neurotrophic factor (BDNF). 
Lau A., Irier, H., Gu J., Tian D., Ku, L., Liu, G., Xia, M., Fritsch, B., Zheng, J., Dingledine, R., Xu, B., Lu, B., Feng, Y. 2010. Proc Natl Acad Sci. Sept 7, 107 (36), 15945-50.

Glutamate Receptor Ion Channels: Structure, Regulation, and Function. 
Traynelis, S., Wollmuth, L., McBain, C., Menniti, F., Vance, K., Ogden, K., Hansen, K., Yuan, H., Myers, S., Dingledine, R. 2010. Pharmacological Reviews, 62, 3, 405-496.

Subunit-dependent modulation of kainate receptors by muscarinic acetylcholine receptors. 
Benveniste, M., Wilhelm, J., Dingledine, R., Mott, D. 2010. Brain Research, Sept 17, 1352, 61-9.

Region-specific changes in gene expression in rat brain after chronic treatment with levetiracetam or phenytoin. 
Hassel, B., Tauboll, E., Shaw, R., Gjerstad, L., Dingledine, R. 2010. Epilepsia, 51, 9, 1714-20.

Neuron-selective changes in RNA transcripts related to energy metabolism in toxic models of parkinsonism in rodents. 
Greene, J., Dingledine, R., Greenamyre, J. 2010. Neurobiology of Disease, 38, 3, 476-81.

Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor. 
Jiang J, Ganesh T, Du Y, Thepchatri P, Rojas A, Lewis I, Kurtkaya S, Li L, Qui M, Serrano G, Shaw R, Sun A, Dingledine R. 2010. Proc Natl Acad Sci. Feb 2;107(5):2307-12.

Subunit Specific Desensitization of Heteromeric Kainate Receptors. 
Mott DD, Rojas A, Fisher JL, Dingledine RJ, Benveniste M. 2010 J Physiol., 588 (4), 683–700.

Control of glutamate receptor 2 (GluR2) translational initiation by its alternative 3' untranslated regions. 
Irier HA, Quan Y, Yoo J, Dingledine R. Mol Pharmacol. 2009 Dec;76(6):1145-9.

Translational regulation of GluR2 mRNAs in rat hippocampus by alternative 3' untranslated regions. 
Irier HA, Shaw R, Lau A, Feng Y, Dingledine R. J Neurochem. 2009 Apr;109(2):584-94.

Quantitative transcriptional neuroanatomy of the rat hippocampus: evidence for wide-ranging, pathway-specific heterogeneity among three principal cell layers. 
Greene JG, Borges K, Dingledine R. Hippocampus. 2009 Mar;19(3):253-64.

Characterization of osteopontin expression and function after status epilepticus. 
Borges K, Gearing M, Rittling S, Sorensen ES, Kotloski R, Denhardt DT, Dingledine R. Epilepsia. 2008 Oct;49(10):1675-85.

Astrocytes in the epileptic brain. 
Wetherington J, Serrano G, Dingledine R. Neuron. 2008 Apr 24;58(2):168-78. Review.

pH-dependent inhibition of kainate receptors by zinc. 
Mott DD, Benveniste M, Dingledine RJ. J Neurosci. 2008 Feb 13;28(7):1659-71.

Evidence against enhanced glutamate transport in the anticonvulsant mechanism of the ketogenic diet. 
Bough KJ, Paquet M, Paré JF, Hassel B, Smith Y, Hall RA, Dingledine R. Epilepsy Res. 2007 May;74(2-3):232-6.

Gene expression changes after seizure preconditioning in the three major hippocampal cell layers. 
Borges K, Shaw R, Dingledine R. Neurobiol Dis. 2007 Apr;26(1):66-77.

Mitochondrial biogenesis in the anticonvulsant mechanism of the ketogenic diet. 
Bough KJ, Wetherington J, Hassel B, Pare JF, Gawryluk JW, Greene JG, Shaw R, Smith Y, Geiger JD, Dingledine RJ. Ann Neurol. 2006 Aug;60(2):223-35.

Degeneration and proliferation of astrocytes in the mouse dentate gyrus after pilocarpine-induced status epilepticus. 
Borges K, McDermott D, Irier H, Smith Y, Dingledine R. Exp Neurol. 2006 Oct;201(2):416-27.

Metabotropic glutamate receptors modulate feedback inhibition in a developmentally regulated manner in rat dentate gyrus.
Doherty JJ, Alagarsamy S, Bough KJ, Conn PJ, Dingledine R, Mott DD. J Physiol. 2004 Dec 1;561(Pt 2):395-401.

Voltage-controlled plasticity at GluR2-deficient synapses onto hippocampal interneurons. 
Laezza F, Dingledine R. J Neurophysiol. 2004 Dec;92(6):3575-81. 

Reciprocal changes of CD44 and GAP-43 expression in the dentate gyrus inner molecular layer after status epilepticus in mice. 
Borges K, McDermott DL, Dingledine R. Exp Neurol. 2004 Jul;188(1):1-10.

Medial perforant path inhibition mediated by mGluR7 is reduced after status epilepticus. 
Bough KJ, Mott DD, Dingledine RJ. J Neurophysiol. 2004 Sep;92(3):1549-57.

Inhibition of glutamate receptor 2 translation by a polymorphic repeat sequence in the 5'-untranslated leaders. 
Myers SJ, Huang Y, Genetta T, Dingledine R. J Neurosci. 2004 Apr 7;24 (14):3489-99.

Neurological disease: listening to gene silencers. 
Roopra A, Huang Y, Dingledine R. Mol Interv. 2001 Oct;1(4):219-28. Review.

Interneuron Diversity series: Interneuron research--challenges and strategies. 
Mott DD, Dingledine R. Trends Neurosci. 2003 Sep;26(9):484-8. Review.

Activity of the rat GluR4 promoter in transfected cortical neurons and glia. 
Borges K, Myers SJ, Zhang S, Dingledine R. J Neurochem. 2003 Sep;86(5):1162-73.

Neuronal and glial pathological changes during epileptogenesis in the mouse pilocarpine model. 
Borges K, Gearing M, McDermott DL, Smith AB, Almonte AG, Wainer BH, Dingledine R. Exp Neurol. 2003 Jul;182(1):21-34.

The roles of metabotropic glutamate receptors in seizures and epilepsy. 
Doherty J, Dingledine R. Curr Drug Targets CNS Neurol Disord. 2002 Jun;1 (3):251-60. Review.

Subunit-dependent modulation of kainate receptors by extracellular protons and polyamines. 
Mott DD, Washburn MS, Zhang S, Dingledine RJ. J Neurosci. 2003 Feb 15;23(4):1179-88.

Functional interactions between cannabinoid and metabotropic glutamate receptors in the central nervous system. 
Doherty J, Dingledine R. Curr Opin Pharmacol. 2003 Feb;3(1):46-53. Review.

Complex effects of CNQX on CA1 interneurons of the developing rat hippocampus. 
Maccaferri G, Dingledine R. Neuropharmacology. 2002 Sep;43(4):523-9.

Altered histone acetylation at glutamate receptor 2 and brain-derived neurotrophic factor genes is an early event triggered by status epilepticus. 
Huang Y, Doherty JJ, Dingledine R. J Neurosci. 2002 Oct 1;22(19):8422-8.

Control of feedforward dendritic inhibition by NMDA receptor-dependent spike timing in hippocampal interneurons. 
Maccaferri G, Dingledine R. J Neurosci. 2002 Jul 1;22(13):5462-72.

Functional organization of the GluR1 glutamate receptor promoter. 
Borges K, Dingledine R. J Biol Chem. 2001 Jul 13;276(28):25929-38.

Reduced excitatory drive onto interneurons in the dentate gyrus after status epilepticus. 
Doherty J, Dingledine R. J Neurosci. 2001 Mar 15;21(6):2048-57.